NO20064854L - Anvendelse av anti-CTLA-4-antistoffer - Google Patents
Anvendelse av anti-CTLA-4-antistofferInfo
- Publication number
- NO20064854L NO20064854L NO20064854A NO20064854A NO20064854L NO 20064854 L NO20064854 L NO 20064854L NO 20064854 A NO20064854 A NO 20064854A NO 20064854 A NO20064854 A NO 20064854A NO 20064854 L NO20064854 L NO 20064854L
- Authority
- NO
- Norway
- Prior art keywords
- ctla
- antibody
- stem cell
- treatment
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55680104P | 2004-03-26 | 2004-03-26 | |
PCT/IB2005/000671 WO2005092380A2 (en) | 2004-03-26 | 2005-03-14 | Uses of anti-ctla-4 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20064854L true NO20064854L (no) | 2006-12-22 |
Family
ID=35056778
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20064854A NO20064854L (no) | 2004-03-26 | 2006-10-25 | Anvendelse av anti-CTLA-4-antistoffer |
Country Status (15)
Country | Link |
---|---|
US (1) | US20050226875A1 (pt) |
EP (1) | EP1732600A2 (pt) |
JP (1) | JP2007530526A (pt) |
KR (1) | KR100845354B1 (pt) |
CN (1) | CN1964739A (pt) |
AR (1) | AR049480A1 (pt) |
AU (1) | AU2005225227A1 (pt) |
BR (1) | BRPI0509274A (pt) |
CA (1) | CA2560919A1 (pt) |
IL (1) | IL177602A0 (pt) |
NO (1) | NO20064854L (pt) |
RU (1) | RU2346702C2 (pt) |
TW (2) | TW200829271A (pt) |
WO (1) | WO2005092380A2 (pt) |
ZA (1) | ZA200607544B (pt) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1863532A1 (en) * | 2005-03-23 | 2007-12-12 | Pfizer Products Incorporated | Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer |
US20080279865A1 (en) * | 2005-03-23 | 2008-11-13 | Pfizer, Inc., Pfizer Products, Inc. | Therapy of Prostate Cancer With Ctla-4 Antibodies and Hormonal Therapy |
WO2006105488A2 (en) | 2005-03-31 | 2006-10-05 | Agensys, Inc. | Antibodies and related molecules that bind to 161p2f10b proteins |
WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
US9738872B2 (en) | 2008-10-30 | 2017-08-22 | Yeda Research And Development Co. Ltd. | Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment |
PT2769737T (pt) * | 2009-07-20 | 2017-06-29 | Bristol Myers Squibb Co | Combinação de um anticorpo anti-ctla4 com etopósido para o tratamento sinérgico de doenças proliferativas |
JP6046494B2 (ja) | 2010-02-08 | 2016-12-14 | アジェンシス,インコーポレイテッド | 161p2f10bタンパク質に結合する抗体薬物コンジュゲート(adc) |
CA2810632C (en) | 2010-09-08 | 2020-06-02 | Yeda Research And Development Co. Ltd. | Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment |
CA2810631A1 (en) * | 2010-09-08 | 2012-03-15 | Yeda Research And Development Co. Ltd. | An immunosuppressive drug combination for a stable and long term engraftment |
EP2621526B1 (en) | 2010-09-29 | 2018-06-06 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to 191p4d12 proteins |
WO2013013029A1 (en) | 2011-07-19 | 2013-01-24 | The Board Of Trustees Of The University Of Illinois | Anti-clta4, anti-glut2 protein for the treatment of type 1 diabetes |
CN103930130B (zh) | 2011-09-08 | 2016-07-06 | 耶达研究及发展有限公司 | 抗第三方中央型记忆t细胞、其产生方法以及其在移植和疾病治疗中的应用 |
JP6434905B2 (ja) | 2012-05-04 | 2018-12-05 | ファイザー・インク | 前立腺関連抗原およびワクチンに基づく免疫療法レジメン |
TR201900694T4 (tr) | 2012-08-23 | 2019-02-21 | Agensys Inc | 158p1d7 proteinlerine bağlanan antikor ilaç konjugatları (adc). |
KR20160060634A (ko) | 2013-08-01 | 2016-05-30 | 어젠시스 인코포레이티드 | Cd37 단백질에 결합하는 항체 약물 컨쥬게이트(adc) |
US10155818B2 (en) | 2014-05-28 | 2018-12-18 | Agenus Inc. | Anti-GITR antibodies and methods of use thereof |
CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
AU2015330731B2 (en) | 2014-10-10 | 2020-07-09 | Idera Pharmaceuticals, Inc. | Treatment of cancer using TLR9 agonist with checkpoint inhibitors |
JP6917902B2 (ja) * | 2015-02-13 | 2021-08-11 | ソレント・セラピューティクス・インコーポレイテッド | Ctla4に結合する抗体医薬 |
TWI719967B (zh) | 2015-03-09 | 2021-03-01 | 美商艾澤西公司 | 結合至flt3蛋白之抗體藥物結合物(adc) |
AU2016271591A1 (en) | 2015-05-29 | 2017-12-21 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
CN108135938A (zh) | 2015-07-16 | 2018-06-08 | 耶达研究及发展有限公司 | 基因修饰的抗第三方中央型记忆t细胞及其在免疫疗法中的用途 |
RU2619208C2 (ru) * | 2015-10-08 | 2017-05-12 | ДИАМОНДЗЛИТЕ ЛИМИТЕД Тридент Чамберс | Способ профилактического лечения при развитии неопластических процессов кожной ткани, таких как меланома, базально-клеточный рак, плоскоклеточный рак |
JP7089470B2 (ja) | 2015-12-02 | 2022-06-22 | アジェナス インコーポレイテッド | 抗体およびその使用方法 |
MX2018011204A (es) | 2016-03-15 | 2019-03-07 | Mersana Therapeutics Inc | Conjugados de anticuerpo-farmaco dirigidos a napi2b y sus metodos de uso. |
EP3478321A4 (en) | 2016-06-30 | 2020-04-22 | Oncorus, Inc. | PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES |
WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
EA201991383A1 (ru) | 2016-12-07 | 2019-12-30 | Эйдженус Инк. | Антитела против ctla-4 и способы их применения |
EP3571295A1 (en) | 2017-01-18 | 2019-11-27 | Yeda Research and Development Co. Ltd | Genetically modified veto cells and use of same in immunotherapy |
US10751368B2 (en) | 2017-01-18 | 2020-08-25 | Yeda Research And Development Co. Ltd. | Methods of transplantation and disease treatment |
WO2018160538A1 (en) | 2017-02-28 | 2018-09-07 | Mersana Therapeutics, Inc. | Combination therapies of her2-targeted antibody-drug conjugates |
MX2020003132A (es) | 2017-09-21 | 2020-07-28 | Eucure Beijing Biopharma Co Ltd | Anticuerpos anti-ctla4 y usos de los mismos. |
US11638760B2 (en) | 2017-11-27 | 2023-05-02 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
CA3085861C (en) * | 2017-12-20 | 2023-09-26 | Harbour Biomed (Shanghai) Co., Ltd | Antibodies binding ctla-4 and uses thereof |
US20220305127A1 (en) | 2017-12-21 | 2022-09-29 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
JP2021508477A (ja) | 2017-12-29 | 2021-03-11 | オンコラス, インコーポレイテッド | 治療用ポリペプチドの腫瘍溶解性ウイルス送達 |
US20200399348A1 (en) * | 2018-02-20 | 2020-12-24 | Emory University | HPV Proteins, Antibodies, and Uses in Managing Abnormal Epithelial Cell Growth |
MX2021004906A (es) | 2018-10-29 | 2021-09-10 | Mersana Therapeutics Inc | Conjugados de anticuerpo modificado con cisteína-fármaco con enlazadores que contienen péptidos. |
AU2020258384A1 (en) | 2019-04-15 | 2021-11-04 | Qwixel Therapeutics Llc | Fusion protein composition(s) comprising targeted masked type I interferons (IFNA and IFNB) and an antibody against tumor antigen, for use in the treatment of cancer |
WO2021066869A1 (en) | 2019-10-04 | 2021-04-08 | TAE Life Sciences | Antibody compositions comprising fc mutations and site-specific conjugation properties |
CA3176356A1 (en) | 2020-04-22 | 2021-10-28 | Anne BROOKS | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
EP4225792A1 (en) | 2020-10-08 | 2023-08-16 | Affimed GmbH | Trispecific binders |
AU2022292462A1 (en) | 2021-06-18 | 2023-12-07 | Nammi Therapeutics, Inc. | FUSION PROTEIN COMPOSITION(S) COMPRISING MASKED TYPE I INTERFERONS (IFNα AND IFNβ) FOR USE IN THE TREATMENT OF CANCER AND METHODS THEREOF |
WO2023007023A1 (en) | 2021-07-30 | 2023-02-02 | Affimed Gmbh | Duplexbodies |
WO2023201369A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
WO2024112571A2 (en) | 2022-11-21 | 2024-05-30 | Iovance Biotherapeutics, Inc. | Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811097A (en) * | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
JP3793693B2 (ja) * | 1998-12-23 | 2006-07-05 | ファイザー インコーポレーテッド | Ctla−4に対するヒトモノクローナル抗体 |
EE05627B1 (et) * | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
EP1212422B1 (en) * | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
IL149701A0 (en) * | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
MXPA04010013A (es) * | 2002-04-12 | 2004-12-13 | Medarex Inc | Metodos de tratamiento utilizando anticuerpos al antigeno-4 asociado con el linfocito t citotoxico. |
-
2005
- 2005-03-14 WO PCT/IB2005/000671 patent/WO2005092380A2/en active Application Filing
- 2005-03-14 BR BRPI0509274-4A patent/BRPI0509274A/pt not_active IP Right Cessation
- 2005-03-14 CA CA002560919A patent/CA2560919A1/en not_active Abandoned
- 2005-03-14 CN CNA2005800098282A patent/CN1964739A/zh active Pending
- 2005-03-14 JP JP2007504498A patent/JP2007530526A/ja not_active Withdrawn
- 2005-03-14 AU AU2005225227A patent/AU2005225227A1/en not_active Abandoned
- 2005-03-14 EP EP05708756A patent/EP1732600A2/en not_active Withdrawn
- 2005-03-14 KR KR1020067019856A patent/KR100845354B1/ko not_active IP Right Cessation
- 2005-03-14 RU RU2006134045/14A patent/RU2346702C2/ru not_active IP Right Cessation
- 2005-03-21 US US11/085,368 patent/US20050226875A1/en not_active Abandoned
- 2005-03-22 AR ARP050101117A patent/AR049480A1/es unknown
- 2005-03-25 TW TW097102213A patent/TW200829271A/zh unknown
- 2005-03-25 TW TW094109392A patent/TW200602078A/zh unknown
-
2006
- 2006-08-21 IL IL177602A patent/IL177602A0/en unknown
- 2006-09-08 ZA ZA200607544A patent/ZA200607544B/en unknown
- 2006-10-25 NO NO20064854A patent/NO20064854L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
RU2006134045A (ru) | 2008-03-27 |
AR049480A1 (es) | 2006-08-09 |
US20050226875A1 (en) | 2005-10-13 |
TW200829271A (en) | 2008-07-16 |
RU2346702C2 (ru) | 2009-02-20 |
CA2560919A1 (en) | 2005-10-06 |
JP2007530526A (ja) | 2007-11-01 |
IL177602A0 (en) | 2006-12-10 |
AU2005225227A1 (en) | 2005-10-06 |
EP1732600A2 (en) | 2006-12-20 |
WO2005092380A2 (en) | 2005-10-06 |
CN1964739A (zh) | 2007-05-16 |
WO2005092380A3 (en) | 2006-06-15 |
KR100845354B1 (ko) | 2008-07-09 |
TW200602078A (en) | 2006-01-16 |
ZA200607544B (en) | 2008-07-30 |
BRPI0509274A (pt) | 2007-09-04 |
KR20070007114A (ko) | 2007-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20064854L (no) | Anvendelse av anti-CTLA-4-antistoffer | |
Hosoyama et al. | Intravenously injected human multilineage-differentiating stress-enduring cells selectively engraft into mouse aortic aneurysms and attenuate dilatation by differentiating into multiple cell types | |
MX2009004238A (es) | Metodos y composiciones para tratamiento de defectos oseos con poblaciones de celulas de placenta. | |
You et al. | Comparative analysis of periprostatic implantation and intracavernosal injection of human adipose tissue‐derived stem cells for erectile function recovery in a rat model of cavernous nerve injury | |
WO2005120557A3 (en) | Inhibition of macrophage-stimulating protein receptor (ron) | |
WO2007035843A3 (en) | Methods and compositions for organ and tissue functionality | |
SV2006002258A (es) | Inmunoterapia de trastornos autoinmunes | |
WO2007056539A3 (en) | Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy | |
GEP20125476B (en) | Compositions of antibodies of dickkopf-1 and use thereof | |
WO2013013025A3 (en) | Anti-cxcr4 antibodies and methods of use | |
ECSP055635A (es) | Agentes citotoxicos que contienen taxanos potentes novedosos y su uso terapeutico | |
NO20083793L (no) | Antistoffer mot amyloid-beta peptid | |
WO2007084775A3 (en) | Compositions and methods for modulation of suppressor t cell activation | |
CL2011000230A1 (es) | Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado. | |
EA200701600A1 (ru) | Способ получения лёгкодоступного клеточного материала из периферической крови и композиция на его основе | |
WO2008096268A3 (en) | Autologous lymph node transfer in combination with vegf-c or vegf-d growth factor therapy to treat secondary lymphedema and to improve reconstructive surgery | |
MX2021009626A (es) | Metodos y composiciones para el tratamiento de gastritis de celulas cebadas, esofagitis de celulas cebadas, enteritis de celulas cebadas, duodenitis de celulas cebadas y/o gastroenteritis de celulas cebadas. | |
Xu et al. | Defocused low-energy shock wave activates adipose tissue-derived stem cells in vitro via multiple signaling pathways | |
MX2021012041A (es) | Metodos para promover la diferenciacion de celulas epiteliales timicas y progenitores de celulas epiteliales timicas de celulas madre pluripotentes, celulas resultantes y usos de estas. | |
WO2021168119A3 (en) | Methods and compositions for identifying and treating subjects at risk of poor cancer survival | |
CR20220465A (es) | Formulaciones de anticuerpos anti-tslp humanos y métodos de uso de los mismos | |
WO2006093860A3 (en) | Method and composition for repairing heart tissue | |
Yang et al. | Co‐overexpression of VEGF and GDNF in adipose‐derived stem cells optimizes therapeutic effect in neurogenic erectile dysfunction model | |
Pakpahan et al. | Stem cell therapy and diabetic erectile dysfunction: a critical review | |
MX2019013137A (es) | Metodos y composiciones para tratar enfermedades oculares alergicas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |